All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How can CRISPR be used for adoptive T-cell therapy in AML?

By Maria Kasimati

Share:

Featured:

Eliana RuggieroEliana Ruggiero

Apr 14, 2021


During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Eliana Ruggiero, IRCCS Ospedale San Raffaele, Milan, IT. We asked, How can CRISPR be used for adoptive T-cell therapy in AML?

How can CRISPR be used for adoptive T-cell therapy in AML?

Ruggiero outlines the concept of adoptive T-cell therapy in AML. She discusses how CRISPR/Cas9 technology has demonstrated promising results in this area, in particular by limiting graft-versus-host disease and transplant-related toxicities.